Open access
Open access
Powered by Google Translator Translator

Randomized Trial: Efficacy of Glecaprevir and Pibrentasvir in Patients with Chronic HCV Genotype 1 Patients After Treatment Failure with NS5A Inhibitor Plus Sofosbuvir Therapy

22 Jan, 2020 | 09:11h | UTC

Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy – Gastroenterology (free)

Editorial: Retreatment Options for Patients Who Failed Direct-Acting Antiviral Regimens Containing NS5A Inhibitors: Is Glecaprevir/Pibrentasvir a Valid and Robust Option? (free)

Source: EvidenceAlerts

 

Related Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.